Abstract Molecular diagnostics in tuberculosis has enabled rapid detection of Mycobacterium tuberculosis complex in clinical specimens, identification of mycobacterial species, detection of drug resistance, and typing for epidemiological investigation. In the laboratory diagnosis of tuberculosis, the nucleic acid amplification (NAA) test is rapid and specific but not as sensitive as culture of mycobacteria. The primary determinant of successful NAA testing for tuberculosis depends on the shedding of mycobacterial DNA in secretions from caseating granulomas and its dissemination into sterile body fluids or tissue biopsies. In multibacillary diseases with a high mycobacterial load, a positive Ziehl-Neelsen smear with a positive NAA test is diagnostic of active tuberculosis, whereas a positive Ziehl-Neelsen smear with a negative NAA test in the absence of inhibitors would indicate nontuberculous mycobacterial disease. The role of the NAA test is more important in paucibacillary diseases with low mycobacterial loads. The presence of polymerase chain reaction (PCR) inhibitors, however, especially in extrapulmonary specimens, may produce false-negative results. Although this problem can be overcome to some extent by extra extraction steps, the additional processing invariably leads to the loss of mycobacterial DNA. To circumvent this problem, a brief culture augmentation step is carried out before the NAA test is performed, which can enhance the mycobacterial load while concomitantly diluting inhibitors, thereby maintaining the sensitivity of the test without excessively increasing turnaround time.
Introduction
Mycobacterium tuberculosis has infected one-third of the world's population and is currently causing 8 million new cases as well as 2 million fatalities per year [1] . In both developing and developed countries, a resurgence of tuberculosis, including multidrug-resistant tuberculosis, has occurred among high-risk populations such as HIV-infected patients [1] .
The control of tuberculosis depends mainly on rapid and accurate diagnosis, provision of effective antituberculous treatment, and thorough contact tracing. Before the introduction of molecular biology into diagnostic mycobacteriology, direct microscopy using a Ziehl-Neelsen smear of early-morning sputum was the only way of making a rapid diagnosis. However, a positive smear requires the presence of about 10 4 acid-fast bacilli (AFB) per milliliter of sputum [2] . Although the sensitivity can be improved by concentrating sputum sediment and applying auramine O fluorescent stain, direct microscopy cannot distinguish between M. tuberculosis and nontuberculous mycobacteria. Therefore, a positive culture of M. tuberculosis remains the gold standard for diagnosis of tuberculosis. Unfortunately, growth on the most affordable solid culture medium, the Lowenstein-Jensen medium, usually takes 4-6 weeks. Moreover, most clinical specimens for culture, such as sputum and bronchoalveolar lavage specimens, require prior decontamination with N-acetyl-L-cysteine and 2% sodium hydroxide, which invariably causes a substantial decrease in the number of colony-forming units of M. tuberculosis [2] . Sensitivity is augmented by the use of a broth culture medium such as the BacT/ALERT system, the Mycobacterial Growth Indicator Tube (MGIT) (containing modified Middlebrook 7H9 broth), the Bactec 460TB system, and the automated analogues of the MGIT and the 460TB systems, i.e. the MGIT 960 and the Bactec 9000 MB, respectively [3] [4] [5] [6] . The mean time to detection of M. tuberculosis in smear-positive specimens was 13.3 days by the MGIT 960 (range 4-39) and 12.7 days by the Bactec 9000 MB (range 7-21) [7] .
Reports of rapid diagnosis of tuberculosis by the detection of various mycobacterial components have not lived up to expectations. The tools employed include gas chromatography-mass spectrometry assay for detection of tuberculostearic acid, and enzyme-linked immunosorbent assay (ELISA) for detection of glycolipid antigen, lipoarabinomannan antigen, and antigen 60 of M. tuberculosis [8] [9] [10] .
Molecular diagnostics in tuberculosis has enabled (i) direct detection of M. tuberculosis complex in clinical specimens, (ii) identification of mycobacteria, (iii) detection of drug resistance of M. tuberculosis, and (iv) DNA typing to differentiate reactivation of disease from exogenous reinfection and to track transmission and internal laboratory contamination. These technological advancements are not intended to replace the conventional tests, but serve rather as important complementary tools in the management of tuberculosis.
Nucleic acid amplification tests for rapid diagnosis of tuberculosis in clinical specimens
In order to diagnose tuberculosis rapidly, manufacturers have developed nucleic acid amplification (NAA) tests specific for M. tuberculosis complex that enable direct detection of the organism in sputum specimens. The two commercially available NAA tests approved by U.S. Food and Drug Administration (FDA), the Amplified Mycobacterium tuberculosis Direct test (MTD test; Gen-Probe, San Diego, CA, USA) and the Cobas Amplicor M. tuberculosis assay (Roche Diagnostics, Mannheim, Germany), had excellent performance when used for testing smear-positive specimens (sensitivity >95%, specificity 100%). The sensitivity was lower (83-85%) when the test was used for testing smear-negative specimens, though the specificity stayed high (99%) [11] . On the basis of these data, the FDA recommended the use of NAA tests only for smearpositive respiratory specimens from patients who had not received antituberculous drugs for 7 or more days or within the last 12 months [12] . Following the initial FDA approval, Gen-Probe enhanced the performance of the MTD test. A large-scale study further revealed the overall sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the enhanced MTD test to be 94.7, 100, 100, and 98.4%, respectively, in respiratory specimens [13] . The corresponding values were 89.4, 100, 100, and 98.3%, respectively, in smear-negative respiratory specimens. This enhanced version of the MTD test was eventually approved by the FDA for testing respiratory specimens, regardless of the smear status.
The Cobas Amplicor M. tuberculosis assay has maintained a reasonable sensitivity and specificity in smearpositive respiratory specimens since its initial approval by the FDA [14] [15] [16] [17] . However, it is limited by a slow block cycler amplification process and time-consuming colorimetric detection of the amplification products, which may affect the turnaround time. Recently, the Cobas Amplicor M. tuberculosis assay integrated real-time techniques using the LightCycler 2.0 instrument (Roche Applied Science, Penzberg, Germany). The procedure for template DNA extraction remains the same as that used in the Cobas Amplicor assay. With the use of the LightCycler instrument to detect the amplification products, the turnaround time can be shortened. In 146 clinical specimens evaluated, good agreement (100% sensitivity, 98.6% specificity) between the LightCycler and Cobas Amplicor assays was reported [18] .
The early studies on NAA tests were largely laboratorybased, emphasizing culture results as a major endpoint, and neglected the integration of available clinical information into the decision-making process [12] . In reality, it is mandatory to consider the degree of clinical suspicion of tuberculosis in determining the clinical utility of NAA tests.
There have been a number of subsequent studies addressing the use of NAA in the clinical setting. One prospective study evaluated the usefulness of the polymerase chain reaction (PCR) to rule out pulmonary tuberculosis in hospitalized patients [19] . Of 85 patients, 27 had cultures positive for M. tuberculosis, 12 of whom were smear positive. A positive PCR on at least one of two specimens collected in the first 24 h was 85 and 74% sensitive and 88 and 93% specific for tuberculosis by the in-house and Roche techniques, respectively. Sensitivity in smear-negative patients was 73 and 53%, respectively. Thus, PCR was found to be a useful tool to evaluate patients for tuberculosis within the first hospital day. In a multicenter prospective trial, a total of 338 patients with symptoms and signs consistent with active pulmonary tuberculosis and complete clinical diagnosis were stratified by the clinical investigators to be at low (≤25%), intermediate (26-75%), or high (>75%) relative risk of having tuberculosis [20] . Based on low, intermediate, and high clinical suspicion of tuberculosis following a comprehensive clinical diagnosis, the sensitivity of the enhanced MTD test was 83, 75, and 87%, respectively, and the corresponding specificity was 97, 100, and 100%. The PPV of the enhanced MTD test was 59% (low), 100% (intermediate), and 100% (high), compared with 36, 30, and 94%, respectively, for the AFB smear. The investigators concluded that, for complex diagnostic problems like tuberculosis, assessments of clinical risk can provide important information about the predictive values more likely to be experienced in clinical practice.
Aside from the commercial NAA tests, a number of inhouse tests have been developed over the years. On the whole, the commercial tests have sensitivity and specificity comparable with that of the in-house tests for respiratory specimens [21, 22] . While originally intended to facilitate early diagnosis of pulmonary tuberculosis, the NAA tests have also been studied extensively in patients with extrapulmonary tuberculosis, using both commercial kits and in-house assays ( In a large-scale study from Sweden that analyzed 154 cerebrospinal fluid samples using the Cobas Amplicor test (Roche), the sensitivity, specificity, PPV, and NPV were 55.6, 97.2, 55.6 and 97.2%, respectively [36] . In the most recently published systematic review and meta-analysis on the diagnostic accuracy of NAA tests for tuberculous meningitis [37] , the overall estimates of sensitivity and specificity in 14 studies utilizing commercial NAA tests were 0.56 and 0.98, respectively. In the 35 studies using inhouse tests, the overall accuracy could not be established with confidence because of wide variability in test accuracy. Thus, on the basis of current evidence, commercial NAA tests show a potential role in confirming the diagnosis of tuberculous meningitis, although their overall low sensitivity possibly precludes exclusion of the disease with certainty [37] .
For pleural effusion, one comparative study of Amplicor PCR versus conventional smear and culture methods failed to show a significant difference in the accuracy of diagnosis [29] . On the other hand, other studies using inhouse PCRs have yielded rather encouraging sensitivities and specificities of ≥70 and ≥90%, respectively [30, 31] .
A recent study using real-time PCR assay in fine-needle aspirates and tissue biopsy specimens for diagnosing mycobacterial lymphadenitis revealed a sensitivity of 72% and a specificity of 100% [27] . The sensitivity is better than that obtained with conventional staining and culture techniques. Thus, this NAA test can provide useful support for clinical decision-making in children with lymphadenitis.
The more recently developed BDProbeTec ET system (BD Biosciences, Sparks, MD, USA) is an automated system characterized by simultaneous DNA amplification (strand displacement amplification) and real-time fluorometric detection of PCR product. An early evaluation of this direct detection system has suggested its usefulness [52, 53] . A recent study of 1,131 clinical specimens (735 respiratory specimens and 396 nonrespiratory specimens) (125 culture positive and 42 smear positive for M. tuberculosis) showed that the overall sensitivity, specificity, PPV, and NPV values were 90.3, 96.9, 78.3, and 98.9%, respectively [54] . A study comparing the performance of the enhanced MTD test with that of the BDProbeTec system has also been conducted [55] . For the enhanced MTD assay, the sensitivity and specificity were 88 and 99.2%, respectively, for respiratory specimens, and 74.3 and 100%, respectively, for extrapulmonary specimens. The corresponding values for the BDProbeTec were 94.5 and 99.6% for respiratory specimens, and 92.3 and 100% for extrapulmonary specimens, respectively. The difference in sensitivity between these two systems was possibly due to better detection of inhibitors by the BDProbeTec system, which has an internal amplification control. A recent study has further suggested the BDProbeTec ET system can be very useful for rapid detection of M. tuberculosis complex, especially in smear-negative respiratory specimens, including pleural fluid [56] . In that study, the sensitivity in smear-positive and smear-negative specimens was 100 and 81.5%, respectively. While data for nonrespiratory specimens are limited, a recent study revealed high sensitivity (84.7%) attained in the diagnosis of tuberculous meningitis [57] .
Data concerning the impact of the M. tuberculosis complex NAA tests on patient outcome have been gathered thus far from uncontrolled studies or observations only, and are not based on well-designed clinical trials. The impact of the NAA tests on patient outcome depends mainly on the status of the AFB smear. In smear-positive patients, hospital infection control and public health resources are largely affected, regarding drug therapy and isolation of hospitalized patients for airborne infections, as well as contact investigations. Appropriate use of isolation beds is especially important in high-prevalence areas or during regional outbreaks, or in any area where such beds are scarce. In smear-negative patients, the NAA test has a greater potential to influence the outcome of patients, since unnecessary treatment and costly and/or risky diagnostic investigations/procedures can be avoided. Thus, the use of molecular diagnostics to detect M. tuberculosis complex has a potential to improve clinical care through a substantial reduction in the time required for mycobacterial detection and, in addition, may provide material savings in the overall cost of patient care.
A cost-effectiveness analysis of the MTD direct test (Gen-Probe) as used routinely on smear-positive respiratory specimens has been published recently [58] . The authors considered that while routine MTD testing of smear-positive specimens would not be expected to produce cost savings for most individual hospitals, centralized reference laboratories might be able to implement MTD testing in a cost-effective manner across a wide range of settings. Prospective studies are required to assess the cost-effectiveness of NAA tests in patients suspected to have tuberculosis. While awaiting more clues for evidence-based practice, one pragmatic approach at present is still to concentrate the use of NAA tests in smear-positive patients with intermediate or low probability of tuberculosis and in smear-negative patients with high or intermediate clinical suspicion of the disease.
Although the NAA tests provide a rapid diagnosis for pulmonary and extrapulmonary tuberculosis, the sensitivity is still far from ideal. The limitation of the utility of NAA tests is largely attributed to the lack of shedding from patients with tuberculosis and the susceptibility of the amplification reaction to the inhibitor. Secretion of antigens from the bacterial cell of M. tuberculosis invariably excites a granulomatous inflammation in immunocompetent hosts that produces a walling-off effect by the epithelioid cells and fibroblasts at the site of infection. This prevents bacteria from being shed and excreted via the luminal passages, such as from the airway into the exterior environment or into body cavities such as the peritoneum, pericardium, pleura, synovium, and arachnoids. Shedding only starts to occur when the granulomatous inflammation is so severe that caseous necrosis has occurred with erosion into the mucosal lumen or coelomic cavity. In the case of the airway, the necrotic material carrying the AFB is carried by the mucociliary blanket and coughed into the environment. It is usually at this stage that a diagnosis can be made in an immunocompetent host using either culture or the NAA test. It is also important to note that extrapulmonary specimens such as whole blood and various body fluids could be more useful clinical specimens in immunosuppressed hosts, since mycobacterial dissemination readily occurs in these individuals without the walling-off effect of granulomatous inflammation. As expected, studies have shown a reasonable sensitivity of NAA tests using peripheral blood in AIDS patients with tuberculosis [45] .
Although the advantage of NAA over culture is that the sensitivity is not decreased by the prior decontamination step, this advantage is offset by inhibitors of the polymerase enzyme. The incidence of such inhibitors varies from 4% in pulmonary specimens to 18.6% in extrapulmonary specimens [59] . Part of this inhibitor problem can be overcome by refining the nucleic acid extraction step. But these extra extraction steps invariably lead to the loss of more mycobacterial DNA. This is a serious problem in extrapulmonary tissue specimens, where inhibitors are especially abundant [59] . This may be circumvented by a short culture augmentation step with concomitant dilution of inhibitors. A brief culture of 2−3 days on LowensteinJensen medium significantly increased the sensitivity of NAA tests in tissue samples exerting PCR inhibition. Sensitivity was 63% before and 92% following brief culture of inhibitory tissue samples [60] . False-positive results of NAA tests can be minimized by automated testing, good laboratory practice, and the use of uracil-Nglycosylase (UNG) and dUTP-UNG [2, 61] . However, biological false-positive results have also been reported as a result of the shedding of dead mycobacteria after adequate antituberculous treatment [62] . Except for the turnaround time, the initial expectations that these NAA tests are at least as rapid as the Ziehl-Neelsen smear, more sensitive and specific than the Ziehl-Neelsen smear, and more sensitive than culture, especially culture of smearnegative specimens from extrapulmonary sites where diagnosis is always difficult due to the paucibacillary nature of the disease, have not been fulfilled [63] .
Rapid identification of mycobacteria by molecular techniques
Identification of mycobacteria by growth characteristics and conventional biochemical tests takes many weeks. The Centers for Disease Control and Prevention (CDC) has recommended the use of more rapid identification methods, such as nucleic acid probes, the NAP (p-nitro-α-acetylamino-β-hydroxypropiophenone) test, and high-performance liquid chromatography [64] .
Several systems exist for the rapid identification of mycobacterial species from cultured isolates [64] . The MicroSeq 500 system (Applied Biosystems, Foster City, CA, USA) is an assay based on sequencing a portion of the 16S rDNA gene [65] [66] [67] . It is time-consuming to perform and requires sophisticated instrumentation for data analysis. The AccuProbe assay (Gen-Probe), a chemiluminescent DNA probe involving hybridization with species-specific probes, is highly specific but can identify only a limited number of species [68] . Like the MicroSeq 500 system, it cannot differentiate M. tuberculosis from the other species in the complex. DNA strip assays based on the reverse hybridization of PCR products to oligonucleotide probes bound on a membrane strip can be applied to identify mycobacterial species. Two commercial DNA strip assays are available [68] . The Inno-LiPA Mycobacteria (Innogenetics NV, Ghent, Belgium) identifies mycobacteria by the 16 to 23S rDNA spacer region of Mycobacterium species [69] , and the GenoType Mycobacteria (Hain Lifescience, Nehren, Germany) identifies mycobacteria by the 23S rDNA of Mycobacterium species [70] . Both can also identify M. tuberculosis from clinical isolates [70, 71] or broth culture systems [72] , but neither allows differentiation between members of the M. tuberculosis complex. A single test can identify a range of species [73] . The Inno-LiPA assay has been recently improved (Inno-LiPA Mycobacteria v2) by increasing the number of identifiable mycobacterial species to 16 [74] . The GenoType assay can identify 13 clinically important mycobacterial species. In a prospective evaluation of 178 clinical isolates, the GenoType assay produced an overall agreement of 89.3% with the AccuProbe assay and 16S rDNA sequencing [70] . Another rapid identification method is PCR amplification-restriction analysis of the rpoB DNA, which can detect pathogenic mycobacteria, including M. tuberculosis complex, in clinical specimens [75] .
Furthermore, an extension of the principle of solid-phase detection of nucleic acids has been developed. Using highdensity DNA probe arrays on a microchip, the system can provide rapid strain identification as well as assessment of drug resistance in cultured isolates [76, 77] . While these microarrays are technologically advanced, the associated costs can be great. One simpler way is to use the peptide nucleic acid probes as an in situ hybridization assay in a fluorescent stain format. Peptide nucleic acids are DNAlike structures in which the sugar-phosphate backbones are replaced with peptide-like structures. The binding of peptide nucleic acid to DNA is sequence specific, and the interaction is stronger than that of a DNA-DNA interaction. This technology has been found to work well for cultured isolates and formalin-fixed histological samples [78, 79] .
Rapid drug susceptibility testing using molecular techniques
Selecting an effective antituberculous drug combination is as important as making a rapid and accurate diagnosis of tuberculosis. Without a rapid method of drug susceptibility testing, most clinicians are prescribing a standard regimen empirically for patients with no known risk factors for drug-resistant disease. Traditionally, testing for drug resistance requires sufficient growth of bacterial colonies in order to allow standardization of inoculums used in the agar proportion method [2] , which usually takes another 2 weeks. The turnaround time is shortened to only 4 days with the Bactec 460TB method, which incorporates standard dilutions of antituberculous drugs (isoniazid, rifampicin, pyrazinamide, ethambutol, and streptomycin) in the broth medium and monitors the growth curve after inoculation [2] .
With unraveling of the genetic basis of antituberculous drug resistance through identification of the main genes in question [80] , namely rpoB (rifampicin), katG (isoniazid), inhA (isoniazid and ethionamide), ahpC (isoniazid), pncA (pyrazinamide), embB (ethambutol), rrs (streptomycin), rpsL (streptomycin), and gyrA (fluoroquinolone), various molecular techniques for detection of drug resistance (largely against rifampicin, isoniazid, pyrazinamide, and streptomycin) in M. tuberculosis have been evaluated. These principally include direct DNA sequencing [81] , heteroduplex analysis [82] , and restriction fragment length polymorphism [83] , as well as oligonucleotide arrays [84] . Two commercial forms of the molecular assays, namely INNOLiPA Rif.TB (Innogenetics) and MisMatch Detect II (Ambion, Austin, TX, USA) have performed well by correlating with standard methods of detection of M. tuberculosis and rifampin susceptibility testing in 94.7% and 100% smear-positive respiratory specimens, respectively [85] . For the cultured isolates, the correlations reached 100%. The former technique is a line-probe assay based on the reverse hybridization principle. The latter represents an RNA/RNA duplex, base pair mismatch assay. Direct DNA sequencing and DNA arrays also appear very promising for future use due to high sensitivity and specificity.
In recent years, there have been additional reports of rapid direct detection of rifampicin and isoniazid resistance in M. tuberculosis strains present in clinical specimens. Most of the techniques embrace the use of improved PCR amplification, such as real-time PCR [86] or allele-specific on-chip PCR [87] . Another new development in recent years has involved the molecular beacons. These are molecules that emit light following a chemical reaction that involves a colored fluorophore [88] . Such molecular beacon assays, based on the binding of DNA primers to specific targets in PCR amplicons, can provide a rapid and sensitive method of detecting drug resistance [89] . However, the application of DNA arrays and molecular beacons is associated with high costs. A recent study described the potential utility of the peptide nucleic acid probes in detecting mutated katG and rpoB genes in M. tuberculosis [90] . This study utilizes the PCR-ELISA format and is likely to be more economical.
Utility of molecular fingerprinting in the diagnosis of tuberculosis
Tuberculosis often has a long incubation period, which makes outbreak investigations more difficult than for other acute respiratory infections. Discriminatory typing methods would have an important place in the confirmation of clusters in outbreak investigations, especially in areas where the disease is highly endemic. Strain typing has been used in community or institutional outbreaks involving family households, prisons, laboratory cross-contamination, and outbreaks due to drug-resistant strains [91] [92] [93] . These typing techniques are also important in the differentiation of reactivation or exogenous reinfection. At the national level, such tests could also be used for the evaluation of regional control programs and will allow the design of more rational control measures. In the last 10 years, the most widely used technique is restriction fragment length polymorphism (RFLP) analysis of chromosomal DNA using IS6110, an insertion sequence found throughout the M. tuberculosis complex, typically in 5-20 copies [94] . While there are general principles regarding interpretation of RFLP patterns, there are no universally accepted criteria. Furthermore, the analysis is labor intensive and cannot be applied to strains with five or fewer copies of IS6110, which are not uncommon in some communities [95] . Other fingerprinting techniques that have been developed to complement RFLP analysis include blotting for polymorphic guanine-cytosine-rich sequences [96] , substituting IS1081 [97] or other repeat sequences such as the variable-number tandem repeats [98] , and spoligotyping [99] .
Other potential uses of molecular diagnostics in tuberculosis
Molecular detection of mycobacterial DNA has also been investigated for its potential to predict treatment success, failure, or relapse. Initially, qualitative PCR on sputum specimens was performed monthly. By 6 months, the majority of the treated patients either did not produce sputum or had a negative PCR test [62] . Around 30% had a persistently positive test, but most of these patients had extensive pulmonary disease or underlying medical problems [62] . A small number of these patients actually had known multidrug-resistant tuberculosis, which accounted for the treatment failure [62] . In most of these patients, the persistently positive tests could be explained by the continual shedding of dead AFB.
Since microbial load is the result of the dynamic interaction between the microbe, the host defense, and the drug treatment, serial quantitative monitoring of the microbial load throughout the course of treatment may be important both for making prognostic predictions and for individualizing the treatment regimen and its duration over the long run. This is possible with the advent of the realtime PCR using the LightCycler (Roche) [100] . However, studies comparing quantitation by AFB smear, colony counts, and genome copies by quantitative PCR showed that the initial bacillary load is well correlated only before treatment. During or after treatment, the rate of disappearance of the AFB and the decrease in the quantity of DNA did not correlate with the rate of decline of the viable colony count and was therefore not useful for monitoring the efficacy of drug treatment. This was not unexpected, since positive smears are well known to persist for years in patients with severe cavitary disease, leading to extensive lung destruction. The hard cell wall of mycobacteria may well have protected the microbial DNA from host enzymatic degradation. There were attempts to use a relatively shorter-lived mRNA encoding the 85kDa protein for monitoring the progress [101] . The clinical usefulness of such an approach requires validation by quantitative PCR in larger clinical studies.
Molecular diagnostics for assessing host susceptibility
The future of the molecular diagnostic tests for tuberculosis will no longer be confined to the bacterial genome. The unfolding of the human genome has led to the discovery of more susceptibility or resistance genes associated with tuberculosis [102] . These genes are related to effective killing of intracellular mycobacteria or granuloma formation. The effector mechanisms include (a) the iron-scavenging function of the macrophage transport proteins, which compete with the siderophores of mycobacteria, and (b) the activation of macrophage function by vitamin D, by the antigen presentation, and even by the cytokines, the cytokine receptors, and the intracellular signaling molecules, which are all part of the immunological pathway of activation for a T-cell helper-1 response [103] . Important examples are the natural resistance-associated macrophage protein (NRAMP-1), the vitamin D receptor, and the HLA-DR2 and HLA-DQB1 loci, located on chromosomes 15 and X [104] [105] [106] . The importance of the mutations involving the receptors IFN R1, IFN R2, STAT1, and IL12R β1, associated with interferon-γ-mediated immunity, is uncertain in tuberculosis, although they have been found to be linked to disseminated diseases due to atypical mycobacteriosis and other intracellular pathogens [107, 108] . The use of microarrays for a host genome survey of tuberculosis susceptibility is not too far from reality.
Conclusion
In the past decade, there has been continual progress in the discovery and evaluation of new techniques in molecular diagnosis for tuberculosis. Many of these techniques are likely to play major complementary roles to the conventional tests. Some technologies have opened up potentially novel approaches in the fight against this important infectious disease worldwide. The use of these new diagnostics is also fraught with budgetary considerations. This is especially relevant in developing countries with heavy disease burdens and severely compromised resources. Thus, continuing efforts must be made to address the clinical applicability and cost-effectiveness of these novel tools in the strategic management of tuberculosis globally. 
